Peptide Research Hub
Use this page in three passes: understand the evidence scale, scan the landmark trials, then compare compounds by study volume.
How we grade confidence
The legend is not decoration. It is the lens for interpreting every profile and every study summary across the site.
Landmark studies
These are the anchor papers that define the current clinical landscape, not just the most recent citations.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% versus placebo in overweight or obese adults with estab...
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide 15 mg once-weekly produced a mean body weight reduction of 22.5% versus 2.4% with placebo in adults with obesity without diab...
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)
Wilding JPH, Batterham RL, Calanna S, et al.
Semaglutide 2.4 mg once-weekly produced 14.9% mean body weight reduction versus 2.4% with placebo in adults with obesity without diabetes.
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women (RECONNECT)
Clayton AH, Althof SE, Kingsberg S, et al.
Bremelanotide (PT-141) 1.75 mg SC increased satisfying sexual events by 0.7 per month versus 0.4 for placebo and significantly reduced di...
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
Marso SP, Daniels GH, Brown-Frandsen K, et al.
Liraglutide 1.8 mg daily reduced MACE by 13% versus placebo in type 2 diabetes patients at high cardiovascular risk.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP, Bain SC, Consoli A, et al.
Once-weekly semaglutide reduced the rate of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% versus placebo in patients with ...
Most researched compounds
Study count is not the same thing as quality, but it is a useful starting point for comparing maturity of evidence.